Selected Articles from This Issue

Abstract

Highlights| August 02 2022 Selected Articles from This Issue Author & Article Information Online ISSN: 1538-8514 Print ISSN: 1535-7163 ©2022 American Association for Cancer Research2022American Association for Cancer Research Mol Cancer Ther (2022) 21 (8): 1259. https://doi.org/10.1158/1535-7163.MCT-21-8-HI Related Content A commentary has been published: Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate A commentary has been published: Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma A commentary has been published: Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression View more A commentary has been published: PLGA–Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record August 2 2022 Citation Selected Articles from This Issue. Mol Cancer Ther 1 August 2022; 21 (8): 1259. https://doi.org/10.1158/1535-7163.MCT-21-8-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search The IDO1/TDO2-AHR pathway drives immunosuppressive tumor microenvironments and high pathway activity is correlated with poor prognosis in many cancer types. AHR is a transcription factor activated by kynurenine and other ligands and is an ideal therapeutic target for reversing the broad immunosuppressive activities mediated by this pathway. McGovern and colleagues introduce IK-175, a selective small molecule that inhibits AHR in vitro and in vivo. IK-175 inhibits tumor growth alone and combined with anti-PD-1 antibodies and reverses immune suppression and increases pro-inflammatory cytokines and effector immune cells in preclinical tumor models. These data provide rationale treating cancer patients with IK-175. Glioblastoma (GBM) remains an incurable malignancy due to treatment resistance and inevitable recurrence. The hypoxic microenvironment in GBM promotes glioma stem cells via epithelial to mesenchymal transition, which are responsible for resistance, recurrence, and invasive nature of GBM. Here, Kannappan and colleagues have shown that Disulfiram, an anti-alcoholism drug effectively inhibits... You do not currently have access to this content.